LB Pharmaceuticals (LBRX) Q3 2025 earnings summary

Executive summary

• Completed IPO in September 2025, raising up to $327.8 million in net proceeds, with all preferred stock converting to common stock.

• Lead product LB-102 is Phase 3-ready for acute schizophrenia, with Phase 3 trial planned for Q1 2026 and topline data expected in H2 2027; Phase 2 trial in bipolar depression also planned for Q1 2026.

• Presented new clinical data at the ECNP Congress, highlighting cognitive and negative symptom benefits of LB-102.

• Expanded leadership with new board and executive appointments to strengthen regulatory and commercialization expertise.

• No product revenue to date; focus remains on R&D for neuropsychiatric indications including bipolar depression.

Financial highlights

• Net loss of $3.6 million for Q3 2025, compared to $14.2 million in Q3 2024; net loss of $13.7 million for the nine months ended September 30, 2025, versus $58.0 million in the prior year period.

• Research and development expenses decreased to $2.4 million in Q3 2025 from $10.7 million in Q3 2024, mainly due to lower clinical trial costs.

• General and administrative expenses were $2.8 million in Q3 2025, down from $5.4 million in Q3 2024.

• Cash, cash equivalents, and marketable securities totaled $314.5 million as of September 30, 2025.

• Total assets as of September 30, 2025 were $320.7 million, up from $33.5 million at December 31, 2024.

Outlook and guidance

• Current cash position expected to fund operations into Q2 2028.

• Phase 3 trial for LB-102 in acute schizophrenia to begin in Q1 2026 with increased sample size to 460 patients; topline data expected in H2 2027.

• Phase 2 trial in bipolar depression to begin in Q1 2026, with topline data expected in Q1 2028.

• Anticipates continued operating losses and negative cash flows as clinical programs advance.